You are here: Home » News-IANS » Health-Medicine
Business Standard

Human cells with 'built-in circuit' can kill cancer cells

IANS  |  London 

Researchers have engineered cells with a "built-in genetic circuit" that produces a molecule that impairs the ability of cells to survive and grow in their low oxygen environment.

The genetic circuit produces the machinery necessary for the production of a compound that inhibits a protein which has a significant and critical role in the growth and survival of tumours.

This results in the cells being unable to survive in the low oxygen, low nutrient tumour micro-environment.

"In a wider sense, we have given these engineered cells the ability to fight back -- to stop a key protein from functioning in cells," said lead researcher Ali Tavassoli, Professor at the University of Southampton in Britain.

"This opens up the possibility for the production and use of sentinel circuits, which produce other bioactive compounds in response to environmental or cellular changes, to target a range of diseases including cancer," Tavassoli said.

As tumours develop and grow, they rapidly outstrip the supply of oxygen delivered by existing blood vessels. This results in cells needing to adapt to a low oxygen environment.

To enable them to survive, adapt and grow in the low oxygen or 'hypoxic' environment, tumours contain increased levels of a protein called Hypoxia-inducible factor 1 (HIF-1).

This protein senses reduced oxygen levels and triggers many changes in cellular function, including a changed metabolism and sending signals for the formation of new blood vessels.

It is thought that tumours primarily hijack the function of this protein (HIF-1) to survive and grow.

"In an effort to better understand the role of HIF-1 in cancer, and to demonstrate the potential for inhibiting this protein in therapy, we engineered a human cell line with an additional genetic circuit that produces the HIF-1 inhibiting molecule when placed in a hypoxic environment," Tavassoli explained.

"We've been able to show that the engineered cells produce the HIF-1 inhibitor, and this molecule goes on to inhibit HIF-1 function in cells, limiting the ability of these cells to survive and grow in a nutrient-limited environment as expected," Tavassoli noted.

The genetic circuit was incorporated onto the chromosome of a human cell line, which encodes the protein machinery required for the production of their cyclic peptide HIF-1 inhibitor.

The research, published in the journal ACS Synthetic Biology, demonstrates the possibility of adding new machinery to human cells to enable them to make therapeutic agents in response to disease signals.

--IANS

gb/bg

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Human cells with 'built-in circuit' can kill cancer cells

Researchers have engineered cells with a "built-in genetic circuit" that produces a molecule that impairs the ability of cancer cells to survive and grow in their low oxygen environment.

Researchers have engineered cells with a "built-in genetic circuit" that produces a molecule that impairs the ability of cells to survive and grow in their low oxygen environment.

The genetic circuit produces the machinery necessary for the production of a compound that inhibits a protein which has a significant and critical role in the growth and survival of tumours.

This results in the cells being unable to survive in the low oxygen, low nutrient tumour micro-environment.

"In a wider sense, we have given these engineered cells the ability to fight back -- to stop a key protein from functioning in cells," said lead researcher Ali Tavassoli, Professor at the University of Southampton in Britain.

"This opens up the possibility for the production and use of sentinel circuits, which produce other bioactive compounds in response to environmental or cellular changes, to target a range of diseases including cancer," Tavassoli said.

As tumours develop and grow, they rapidly outstrip the supply of oxygen delivered by existing blood vessels. This results in cells needing to adapt to a low oxygen environment.

To enable them to survive, adapt and grow in the low oxygen or 'hypoxic' environment, tumours contain increased levels of a protein called Hypoxia-inducible factor 1 (HIF-1).

This protein senses reduced oxygen levels and triggers many changes in cellular function, including a changed metabolism and sending signals for the formation of new blood vessels.

It is thought that tumours primarily hijack the function of this protein (HIF-1) to survive and grow.

"In an effort to better understand the role of HIF-1 in cancer, and to demonstrate the potential for inhibiting this protein in therapy, we engineered a human cell line with an additional genetic circuit that produces the HIF-1 inhibiting molecule when placed in a hypoxic environment," Tavassoli explained.

"We've been able to show that the engineered cells produce the HIF-1 inhibitor, and this molecule goes on to inhibit HIF-1 function in cells, limiting the ability of these cells to survive and grow in a nutrient-limited environment as expected," Tavassoli noted.

The genetic circuit was incorporated onto the chromosome of a human cell line, which encodes the protein machinery required for the production of their cyclic peptide HIF-1 inhibitor.

The research, published in the journal ACS Synthetic Biology, demonstrates the possibility of adding new machinery to human cells to enable them to make therapeutic agents in response to disease signals.

--IANS

gb/bg

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Human cells with 'built-in circuit' can kill cancer cells

Researchers have engineered cells with a "built-in genetic circuit" that produces a molecule that impairs the ability of cells to survive and grow in their low oxygen environment.

The genetic circuit produces the machinery necessary for the production of a compound that inhibits a protein which has a significant and critical role in the growth and survival of tumours.

This results in the cells being unable to survive in the low oxygen, low nutrient tumour micro-environment.

"In a wider sense, we have given these engineered cells the ability to fight back -- to stop a key protein from functioning in cells," said lead researcher Ali Tavassoli, Professor at the University of Southampton in Britain.

"This opens up the possibility for the production and use of sentinel circuits, which produce other bioactive compounds in response to environmental or cellular changes, to target a range of diseases including cancer," Tavassoli said.

As tumours develop and grow, they rapidly outstrip the supply of oxygen delivered by existing blood vessels. This results in cells needing to adapt to a low oxygen environment.

To enable them to survive, adapt and grow in the low oxygen or 'hypoxic' environment, tumours contain increased levels of a protein called Hypoxia-inducible factor 1 (HIF-1).

This protein senses reduced oxygen levels and triggers many changes in cellular function, including a changed metabolism and sending signals for the formation of new blood vessels.

It is thought that tumours primarily hijack the function of this protein (HIF-1) to survive and grow.

"In an effort to better understand the role of HIF-1 in cancer, and to demonstrate the potential for inhibiting this protein in therapy, we engineered a human cell line with an additional genetic circuit that produces the HIF-1 inhibiting molecule when placed in a hypoxic environment," Tavassoli explained.

"We've been able to show that the engineered cells produce the HIF-1 inhibitor, and this molecule goes on to inhibit HIF-1 function in cells, limiting the ability of these cells to survive and grow in a nutrient-limited environment as expected," Tavassoli noted.

The genetic circuit was incorporated onto the chromosome of a human cell line, which encodes the protein machinery required for the production of their cyclic peptide HIF-1 inhibitor.

The research, published in the journal ACS Synthetic Biology, demonstrates the possibility of adding new machinery to human cells to enable them to make therapeutic agents in response to disease signals.

--IANS

gb/bg

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard